MAY 2 5 2006 Substitute (Modifie

Substituted rm PTO-1449

U.S. Department of Commerce Patent and Trademark Office Attorney's Docket No. 14875-151US1

September 28, 2005

Application No. 10/550,934

Information Disclosure Statement by Applicant (Use several sheets if necessary) Applicant
Masayuki Tsuchiya et al.
Filing Date

Group Art Unit

(37 CFR §1.98(b))

U.S. Patent Documents Filing Date Examiner Desig. Document Publication Initial Number Date Patentee Class Subclass If Appropriate ID /AMG/ AA 6.183,744 02/06/2001 Goldenberg /AMG/ AB 6.368,596 04/09/2002 Ghetie et al. /AMG/ AC 2003/0148409 08/07/2003 Rossi et al.

Foreign Patent Documents or Published Foreign Patent Applications									
Examiner		Desig.	Document	Publication	Country or			Translation	
Initia	al	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
/AMG/	i/	AD	JP 10-505231	05/26/1998	Japan			see AG	
Т		AE	JP 2001-518930	10/16/2001	Japan			see AH	
		AF	JP 2002-544173	12/24/2002	Japan			see AI	
		AG	WO 96/04925	02/22/1996	WIPO				
		AH	WO 98/42378	10/01/1998	WIPO				
\top		AI	WO 00/67795	11/16/2000	WIPO				
		AJ	WO 01/74388	10/11/2001	WIPO				
		AK	WO 01/97858	12/27/2001	WIPO				
		AL	WO 02/04021	01/17/2002	WIPO				
		AM	WO 02/22212	03/21/2002	WIPO				
V		AN	WO 03/033654	04/24/2003	WIPO				
/AMG	1/	AO	WO 03/104425	12/18/2003	WIPO				

	Other D	ocuments (include Author, Title, Date, and Place of Publication)	
Examiner Initial	Desig. ID	Document	
/AMG/	AP	Fayen et al., "Negative signaling by anti-HLA class I antibodies is dependent upon two triggering events," Int. Immunol., 10:1347-1358 (1998)	
	,AQ	Funaro et al., "Monoclonal antibodies and therapy of human cancers," Biotechnol. Adv., 18:385-401 (2000)	
	· AR	Genestier et al., "Fas-Independent Apoptosis of Activated T Cells Induced by Antibodies to the HLA Class I al Domain," Blood, 90:3629-3639 (1997)	
,,	AS	Holliger et al., "'Diabodies': Small bivalent and bispecific antibody fragments," Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)	
/AMG/	AT	Hu et al., "Minibody: A Novel Engineered Anti-Carcinoembryonic Antigen Antibody Fragment (Single-Chain Fv-C ₃) Which Exhibits Rapid, High-Level Targeting of Xenografts," Cancer Res., 56:3055-3061 (1996)	

Examiner Signature /Anne M. Gussow/ Date Considered 05/28/2008

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with

Substitute Form PTO-1449 (Modified)			Application No. 10/550,934	
	closure Statement	Applicant Masayuki Tsuchiya et al.		
(Use several s (37 CFR §1.98(b))	heets if necessary)	Filing Date September 28, 2005	Group Art Unit	

Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.			
Initial	ID	Document		
/AMG/	AU	Kreiman et al., "Cytotoxic Activity of Disulfide-stabilized Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) toward Fresh Malignant Cells from Patients with B-Cell Leukemias," Clin. Cancer Res., 6:1476-1487 (2000)		
	AV	Matsuoka et al., "A Novel Type of Cell Death of Lymphocytes Induced by a Monoclonal Antibody without Participation of Complement," J. Exp. Med., 181:2007-2015 (1995)		
	AW	Ohtomo et al., "Molecular Cloning and Characterization of a Surface Antigen Preferentially Overexpressed on Multiple Myeloma Cells," <i>Biochem. Biophys. Res. Commun.</i> , 258:583-591 (1999)		
	AX	Ono et al., "The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity," Mol. Immunol., 36:387-395 (1999)		
/AMG/	AY	Ozaki et al., "Humanized Anti-HM1.24 Antibody Mediates Myeloma Cell Cytotoxicity That Is Enhanced by Cytokine Stimulation of Effector Cells." <i>Blood</i> , 93:3922-3930 (1999)		

Examiner Signature /Anne M. Gussow/	Date Considered 05/28/2008
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	t in conformance and not considered. Include copy of this form with